Crossmark

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib

Crossref DOI link: https://doi.org/10.1007/s00277-018-3569-1

Published Online: 2018-12-04

Published Print: 2019-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Breccia, Massimo

Bartoletti, Daniela https://orcid.org/0000-0003-2036-2896
Bonifacio, Massimiliano

Palumbo, Giuseppe A.

Polverelli, Nicola

Abruzzese, Elisabetta

Bergamaschi, Micaela

Tieghi, Alessia

Tiribelli, Mario

Iurlo, Alessandra

Cavazzini, Francesco

Sgherza, Nicola

Binotto, Gianni

Isidori, Alessandro

D’Adda, Mariella

Crugnola, Monica

Bosi, Costanza

Heidel, Florian

Molica, Matteo

Scaffidi, Luigi

Cattaneo, Daniele

Latagliata, Roberto

Auteri, Giuseppe

Lemoli, Roberto M.

Fanin, Renato

Russo, Domenico

Aversa, Franco

Cuneo, Antonio

Semenzato, Gianpietro

Catani, Lucia

Cavo, Michele

Vianelli, Nicola

Foà, Robin

Palandri, Francesca
License Information

Text and Data Mining valid from 2018-12-04
More Information

Article History

Received: 20 September 2018

Accepted: 26 November 2018

First Online: 4 December 2018

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5).

: Informed consent was obtained from all patients for being included in the study.